buoy strong drug group sale johnson
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data sep
rate updat sep
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad psoriasi drug
stelara medic devic group bring one third
sale compani hold control posit mani
area includ orthoped ethicon endo-surgeri surgic
devic consum divis larg round remain
busi line despit manufactur issu past
sever year group still hold mani brand strong price
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
minim invas surgic tool
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm drug
divis focus follow therapeut area immunolog oncolog
neurolog pulmonari cardiolog metabol diseas devic
segment focus orthoped surgeri tool vision care
smaller area last segment consum focus babi care beauti
oral care over-the-count drug women health geograph
close half total revenu gener within unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
buoy strong drug group sale
line expect consensu
expect major chang fair valu
estim continu view stock larg fairli
valu invest commun appreci
compani strength weak quarter steadi
result reaffirm wide moat rate
led strong drug sale total sale increas
oper year year drug group
growth slightli higher expect driven
robust immunolog oncolog drug sale howev
expect growth therapeut area moder
expect price declin immunolog drug
remicad due biosimilar pressur estim
caus remicad price declin close alreadi
also expect growth immunolog drug stelara
stagnat share gain crohn indic led
strong clinic data off-set share loss psoriasi
due increas competit drug oncolog
increas gener competit zytiga expect
fourth quarter ahead manag guidanc velcad
expect pressur compani overal
cancer drug sale outsid drug modest growth
consum devic larg expect
competit pressur weigh growth
expect trend continu
eps increas strong sale
gain higher margin drug group help amplifi growth
bottom line expect trend continu
johnson johnson drug unit best posit growth
next three year addit face
potenti heavi legal charg firm talcum
powder potenti caus cancer expect johnson
johnson litig case aggress final
relat payment caus major impact
complet overview compani posit
immunolog oncolog therapeut area well
deep dive compani pipelin pleas see
threat secur pharma moat
increas fair valu estim per share
base improv outlook overal margin
partli driven strong margin compani drug
divis within core driver cash flow new
immunolog oncolog drug drive growth
includ actelion acquisit expect annual
earn per share growth averag next
five year strong growth new pipelin drug
off-set patent loss pharmaceut divis
near term result actelion acquisit
bring high-margin drug also expect wane
cost-remedi effort consum group
increas cost-contain effort throughout firm
help off-set margin pressur due loss patent
protect sever high-margin drug
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
success drug pipelin along magnitud
market pressur current market drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
total sale respect addit within
segment one product domin sale lipitor
despit carri lower-margin divis
maintain strong price power post gross
margin past five year valid
strong competit posit
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ
minim invas surgic tool help maintain
leadership sever medic devic area well
remain high sever devic product
exampl physician switch vendor hip knee
devic could take week month learn new
product keep physician tie compani
consum side new product
advanc combin solid brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
lower drug price reduc coverag less innov
drug forc drug firm push true innov
reduc power compani distribut network
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround devic also weigh certainti
believ johnson johnson carri one widest
moat healthcar sector support intellectu
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
role number segment includ medic devic
over-the-counter medicin sever drug market
compani overli depend one particular oper
segment pharmaceut busi medic devic
group consum product repres
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
pipelin strong entrench medic devic
consum good give firm relief
pressur drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth major near-term patent loss
product hard manufactur includ
biolog drug remicad limit gener
oproduct litig manufactur issu
power brand name segment brand
recognit import
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard product recal hip knee
replac along sever consum product
could damag compani brand power cost
billion dollar creat distract
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector recent acquisit
actelion put dent compani cash balanc
annual free cash flow approach billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever roadblock
product metal-on-met hip knee implant
sever product recal could damag sterl
reput longer term compani face typic
healthcar risk reduc price power
govern pharmaci benefit manag regulatori
delay nonapprov well increasingli aggress
gener competit small-molecul drug
biolog particular biosimilar risk remicad
increas sever biosimilar work gain market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
take-over price rel fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trump blueprint lower drug price offer minor
chang pharma biotech moat impact
administr blueprint lower drug price reduc
out-of-pocket cost offer propos dont impact
moat rate pharma industri
price power brand drug still look
transpar provid inform help
patient lower out-of-pocket cost believ
limit impact brand drug price mild
polici propos appear larg build
budget propos drug white paper issu
council econom advisor februari aggreg
think propos would like impact less
drug spend exclud potenti chang
negoti medicar part drug could offer
anoth reduct drug spend depend
exact implement
overal blueprint propos creat minor headwind
brand drug price regard propos increas
gener competit view brand drug
industri tactic
limit gener competit
rel ineffect gener biolog biosimilar
larg assum swift competit follow patent
loss alreadi line polici effort
increas gener competit hard-to-mak drug
polici propos limit use risk evalu
mitig strategi delay gener competit rare
use could potenti impact drug firm
exampl celgen key drug revlimid could face
addit gener rapid launch gener
review fda
propos increas negoti around part drug
look like substant propos drug
histor face much price pressur note
drug tend least interchang
competit make negoti drug price
difficult polici propos regard incent
lower drug list price price transpar
direct-to-consum ad inform view
limit potenti reduc price lastli
focu lower out-of-pocket drug cost allow
cost-sav inform pharmacist provid
inform lower-cost altern treatment option
medicar patient could provid minor cost save
would significantli alter price power brand
within polici propos beyond immedi
action outlin administr provid
opportun explor addit cost save
granular propos limit view
major addit opportun focus
close rel smaller price loophol explor
altern price model value-bas
reimburs new strategi around medicaid drug
price believ innov brand drug
abl thrive environ major current
brand drug develop alreadi focus
innov meet increas demand privat sector
payer pharmaci benefit manag pbm
addit two opportun explor could
significantli help brand drugmak first propos
limit abil pbm reli rebat drug firm
lower drug cost could forc transpar
upfront price discount potenti give drug firm
power set price second effort make
countri pay drug hold potenti increas
global price power view initi larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
polit driven difficult implement
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued
trump drug look modestli lower drug price
keep pharma biotech moat intact may
trump polici speech lower drug price didnt offer
mani specif focus mostli reduc middleman
profit rais drug price oversea base
 govern budget propos council
econom advisor white paper drug polici expect
modest neg headwind brand drug price
continu view moat within pharma/biotech
industri intact support strong price power
patent protect drug view brand drug group
aggreg under-valued expect group digest
modest price headwind major impact
valuat view roch sanofi allergan
under-valued wide moat drug firm
biggest neg seen administr
propos shift medicar part drug part
scenario price decreas drug
pharma earn would like fall close
heavier hit firm exposur
drug channel regeneron beyond
polici modestli neg polici propos includ
test new price program medicaid modifi
exclus rule increas gener competit
increas medicar part negoti power
modifi payment structur medicar part
exclud shift part medicar
estim save initi look like less
 drug spend
posit polici propos brand drug
offer well implement seem unlik
notabl demand countri pay drug
seem difficult implement also break
pharmaci benefit manag increas competit would
like give drug compani power drug price
howev either polici implement
would expect major windfal brand drug industri
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
led drug group post solid
result lead slight fve increas apr
johnson johnson report solid first-quart result
sale exceed expect
consensu expect increas fair valu
estim close howev view stock
fairli valu expect cash flow larg reflect
current stock price compani continu support
wide moat strength pharmaceut
divis lead overal sale growth quarter
compani divers line-up lead drug continu
off-set near-term patent loss drive long-term
growth support high return invest capit
quarter oper drug divis growth
exceed expect solid growth oncolog
immunolog particular immunolog drug stelara
tremfya post strong gain support gain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
crohn diseas psoriasi respect
expect close normal declin immunolog
drug remicad continu due biosimilar pressur
new immunolog drug mitig pressur
also oncolog darzalex continu post strong gain
expect drug develop major blockbust
drug move earlier line multipl myeloma
expect gener competit prostat cancer
zytiga later year ahead manag guidanc
compani strong portfolio cancer drug off-set
rel drug group medic consum
group post slower oper growth
respect expect growth divis
acceler closer long term new
product introduc addit brand campaign
launch particular new product eyecar
segment continu support robust growth also
expect neg pressur babi care market
reced market support reinforc compani
strong brand power industri
complet overview compani posit
immunolog oncolog therapeut area well
deep dive compani pipelin pleas see
threat secur pharma moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
